Immediate Impact
74 standout
Citing Papers
Changing etiology and epidemiology of hepatocellular carcinoma: Asia and worldwide
2024 Standout
Polymeric Nanoparticles for Drug Delivery
2024 Standout
Works of Mark Karwal being referenced
Phase II, Open-Label Study of Brivanib as First-Line Therapy in Patients with Advanced Hepatocellular Carcinoma
2011
FDG-PET appearance of pelvic Castleman's disease.
1997
Author Peers
| Author | Last Decade | Papers | Cites | |||
|---|---|---|---|---|---|---|
| Mark Karwal | 141 | 120 | 110 | 26 | 322 | |
| Daniel Almquist | 166 | 102 | 101 | 18 | 292 | |
| Burcin Özdirik | 108 | 99 | 150 | 24 | 303 | |
| Anna Castiglione | 66 | 54 | 68 | 19 | 357 | |
| Yongwen Song | 193 | 86 | 35 | 26 | 337 | |
| Francesca Comito | 127 | 96 | 58 | 25 | 320 | |
| David Hsiehchen | 191 | 102 | 70 | 34 | 320 | |
| Sally L. George | 111 | 44 | 61 | 23 | 306 | |
| F Latteri | 61 | 154 | 107 | 24 | 293 | |
| Yoshinari Matsuda | 130 | 29 | 37 | 22 | 306 | |
| Lei Yuan | 114 | 96 | 59 | 31 | 364 |
All Works
Login with ORCID to disown or claim papers
Loading papers...